Evidence map›Paper›PMID 25894501›Full record

ArticleNature genetics2015

DNA replication fidelity in Mycobacterium tuberculosis is mediated by an ancestral prokaryotic proofreader.

Jeremy M Rock, Ulla F Lang, Michael R Chase, Christopher B Ford, Elias R Gerrick, Richa Gawande, Mireia Coscolla, Sebastien Gagneux, Sarah M Fortune, Meindert H Lamers

Open access · greenAbstract read
In one paragraph

Article in Nature genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 77 citations in OpenAlex.

  1. Article
  2. Hypermutability ofEmerging microbes & infections · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. An additional proofreader contributes to DNA replication fidelity in mycobacteria.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The essentialScience advances · 2022
    Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Jeremy M RockDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA.
Ulla F LangMedical Research Council (MRC) Laboratory of Molecular Biology, Cambridge, UK.
Michael R ChaseDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA.
Christopher B Ford1] Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA. [2] Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Elias R GerrickDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA.
Richa GawandeDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA.
Mireia Coscolla1] Swiss Tropical and Public Health Institute, Basel, Switzerland. [2] University of Basel, Basel, Switzerland.
Sebastien Gagneux1] Swiss Tropical and Public Health Institute, Basel, Switzerland. [2] University of Basel, Basel, Switzerland.
Sarah M Fortune1] Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA. [2] Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. [3] Ragon Institute of Massachusetts General Hospital, Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Meindert H LamersMedical Research Council (MRC) Laboratory of Molecular Biology, Cambridge, UK.
Harvard University · USSwiss Tropical and Public Health Institute · CHBroad Institute · USMedical Research Council · GBMRC Laboratory of Molecular Biology · GB

Funding

ZWITTERION SURFACTANT DDMAB FOR IMPROV STABIL OF PROTEINP41RR001209 · NCRR · STANFORD UNIVERSITY · PI GONZALEZ, ANA M · 1985 to 2011
$38.9M
Sequencing CoreU19AI109755 · NIAID · HARVARD MEDICAL SCHOOL · PI CHANDLER, DARRELL P, CULHANE, AEDIN C · 2014 to 2018
$29.1M
Real-time surveillance to support dynamic and predictive models of MDR/XDR TBU19AI076217 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI MURRAY, MEGAN B · 2007 to 2011
$13.5M
Medical Research Council MC_U105197143NCCDPHP CDC HHS 1DP20D001378NCRR NIH HHS P41 RR001209NIAID NIH HHS AI109755-01NIAID NIH HHS U19 AI076217NIAID NIH HHS U19AI076217NIAID NIH HHS U19 AI109755
6 · The paper itself

Abstract

The DNA replication machinery is an important target for antibiotic development in increasingly drug-resistant bacteria, including Mycobacterium tuberculosis. Although blocking DNA replication leads to cell death, disrupting the processes used to ensure replication fidelity can accelerate mutation and the evolution of drug resistance. In Escherichia coli, the proofreading subunit of the replisome, the ɛ exonuclease, is essential for high-fidelity DNA replication; however, we find that the corresponding subunit is completely dispensable in M. tuberculosis. Rather, the mycobacterial replicative polymerase DnaE1 itself encodes an editing function that proofreads DNA replication, mediated by an intrinsic 3'-5' exonuclease activity within its PHP domain. Inactivation of the DnaE1 PHP domain increases the mutation rate by more than 3,000-fold. Moreover, phylogenetic analysis of DNA replication proofreading in the bacterial kingdom suggests that E. coli is a phylogenetic outlier and that PHP domain-mediated proofreading is widely conserved and indeed may be the ancestral prokaryotic proofreader.

Indexed as

DNA ReplicationAmino Acid SequenceAntitubercular AgentsBacterial ProteinsDNA, BacterialDNA Polymerase IIIDrug Resistance, BacterialMicrobial Sensitivity TestsMolecular Sequence DataMycobacterium tuberculosisPhenotypePhylogenyPolymorphism, Single NucleotideAntitubercular AgentsBacterial ProteinsDNA, BacterialDNA Polymerase IIIDNA polymerase III, alpha subunit

Identifiers

PMID25894501
PMCPMC4449270
OpenAlexW2094461142

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.